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Diabetes is associated with genotypically drug-resistant tuberculosis 
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Diabetes is associated with failure of tuberculosis (TB) treatment, but it is unclear whether this 
is related to genotypic drug resistance of the infecting mycobacteria. We used whole genome 
sequencing (WGS) to examine 1,365 known drug resistance mutations in 896 Mycobacterium 
tuberculosis isolates from TB patients that were screened for diabetes using HbA1c testing as 
part of the TANDEM project [1]. Ethical approval was received from the London School of 
Hygiene and Tropical Medicine and institutional review boards in Indonesia and Peru. In Peru 
we selected all available M. tuberculosis isolates from TANDEM patients (44 with and 445 
without diabetes), and in Indonesia we selected all available isolates from diabetic patients 
(n=115) plus a subset of isolates from non-diabetic patients (n=292) from the same clinics, 
during the same time period, frequency-matched by age. We used TB Profiler version 0.3.8 [2] 
to determine M. tuberculosis lineage and drug resistance. A phylogeny was constructed using 
PhyML version 3.0 [3], and the minimum pairwise distance for isolates was calculated 
separately for patients with and without diabetes, stratified by country. We examined if 
diabetes was associated with genotypic drug resistance against individual drugs or with MDR-
TB for the two countries separately and combined, with multilevel multivariable logistic 
regression, taking into account the country of origin and adjusting for age, gender, HIV-
infection, previous TB treatment, and M. tuberculosis lineage. In additional analyses we 
examined the effect of HbA1c level, and stratified results for new versus known diabetes. For 
comparison of specific drug resistance mutations we used univariate and country-stratified 
analysis because of small numbers. We also addressed the hypothesis that isolates from patients 
with diabetes would have fewer mutations compensating for loss of fitness associated with drug 
resistance, noting that diabetes leads to lower host immune defence against M. tuberculosis [4]. 
For this analysis, all non-synonymous SNPs in rpoA, rpoB outside the rifampicin resistance-
determining region (RRDR), rpoC, ahpC promoter region and ubiA were considered as 
mutations potentially compensating for the loss of fitness caused by drug resistance mutations 
[5]. More detailed methods are provided as supplementary material 
(10.6084/m9.figshare.9884303). 
Diabetes was more common among Indonesian patients, and drug resistance more common in 
Peru. TB patients with diabetes were older, more often female, and slightly heavier than TB 
patients without diabetes, and fewer diabetic patients reported a previous history of TB 
treatment compared to those without diabetes (Table). Diabetes was not associated with a 
particular M. tuberculosis lineage or with genotypic clustering; the median minimum pairwise 
distance for isolates from diabetic and non-diabetic patients was 164 respectively 161 SNPs in 
Indonesia, and 98 respectively 67 SNPs in Peru. Drug resistance mutations were found in 
isolates of 21 / 115 (18%) diabetic and 44 / 292 (15%) non-diabetic patients in Indonesia, and 
17 / 44 (39%) diabetic and 88 / 445 (20%) non-diabetic patients in Peru. In multilevel 
multivariable logistic regression, diabetes was the only factor significantly associated with 
genotypic drug resistance against at least one drug (OR 1.8; 95% CI 1.1-2.9). The association 
between diabetes and drug resistance was similar for patients with new (adjusted OR 2.0; 95% 
CI 0.9-4.4) and previously diagnosed diabetes (OR 1.7; 95% CI 0.98-2.9), and not dependent on 
the HbA1c level (not shown). The relation between diabetes and resistance was still present 
after exclusion of 19 HIV-infected patients (adjusted OR 1.8; 95% CI 1.1-2.9). At the level of 
individual drugs, diabetes was significantly associated with rifampicin resistance (OR 2.5; 95% 
CI 1.2-5.3; Supplementary Figure (10.6084/m9.figshare.9884303)), also among patients not 
previously treated for TB (OR 3.1; 95% CI 1.2-8.3, data not shown). We also found more 
fluoroquinolone resistance in diabetic TB patients, and this difference reached statistical 
significance for Peru (OR 6.69; 95% CI 1.37-32.68; Supplementary Figure). We did not find 
evidence of interaction between rifampicin and fluoroquinolone resistance in the multilevel 
multivariable model (Pinteraction = 0.232, data not shown). Finally, although this association did 
not reach statistical significance, the odds of MDR-TB were twice as high in diabetic versus non-
diabetic patients (OR 2.09; 95% CI 0.92-4.77; Supplementary Figure). 
Examining individual drug resistance mutations (Table), diabetes among TB patients in Peru 
was associated with more mutations in Rv1482c-fabG1 (p<0.01), which confers resistance to 
isoniazid and ethionamide, and gyrA (P<0.05), which accounts for fluoroquinolone resistance; 
rpoB mutations leading to rifampicin resistance also appeared more common in diabetes 
patients (15.9% vs. 9.4%; p=0.069). In Indonesia, drug resistance was less common and no 
significant association was found between diabetes and specific resistance mutations. With 
regard to compensatory mutations, no differences were found in the association between 
isoniazid or rifampicin resistance mutations and potential compensatory mutations between 
patients with and without diabetes, and no interaction was found between diabetes and the 
presence of compensatory mutations (data not shown). 
Our findings are in line with previous studies that used phenotypic drug susceptibility testing 
(DST) and focused on isoniazid and rifampicin (reviewed in Tegegne et al. [6]). Several factors 
might account for the observed association between diabetes and drug resistance mutations. 
First, people with diabetes might be at higher risk of nosocomial transmission of drug-resistant 
tuberculosis in low-resource settings [7]; unfortunately we did not have the data to compare 
prior hospitalization for diabetes compared to non-diabetes tuberculosis patients. Second, 
lower rifampicin plasma concentrations among diabetes patients that were found in some [8] 
but not all [9] studies might lead to acquisition of drug resistance. However, all isolates in our 
study were collected before start of treatment, only 26% of patients with a drug-resistant 
isolate reported an episode of previous TB treatment that might have resulted in acquired drug 
resistance mutations, and differences were also present among patients with a first episode of 
TB. We cannot exclude misclassification of TB treatment history, as this was self-reported and 
as some patients previously treated for TB may in fact have had another illness. However it is 
unlikely that possible misclassification of patients regarding TB treatment history explains the 
association between drug resistance mutations and diabetes, as it was evident both among 
patients with and without a history of previous TB treatment. Third, recent papers have found an 
interaction between drug resistance and cellular immunometabolism [10], and this interaction 
might be altered by diabetes. Fourth, similar to HIV, reduced host defence in people with 
diabetes might increase the risk of developing active TB caused by Mycobacterium tuberculosis 
strains with drug resistance mutations associated with loss of fitness [11], although we could 
not confirm this when looking at previously reported resistance-compensating mutations. The 
trend towards more fluoroquinolone resistance in TB patients with diabetes could be related to 
frequent use of fluoroquinolones for respiratory infections, which may be more common for 
those with diabetes [12]. 
In contrast to studies using phenotypic DST, WGS allowed us not only to investigate the 
association between diabetes and drug resistance at the gene level, but also to take the diverse 
M. tuberculosis genetic background into account. However, our study could not prove if diabetes 
is associated with more transmission of drug-resistance, as the sampling fraction of M. 
tuberculosis isolates was probably too low to identify transmission clusters. Besides higher rates 
of transmission, diabetes may also lead to more TB reactivation caused by drug-resistant 
strains. 
In summary, for the first time, we used M. tuberculosis whole genome sequencing data from two 
countries to study the association between diabetes and genotypic drug resistance in TB 
patients. Diabetes was associated with an increased risk of disease caused by strains with 
resistance mutations, particularly against rifampicin, but also against isoniazid, ethionamide 
and fluoroquinolones. Higher rates of resistance mutations among diabetic TB patients could 
not be explained by previous TB treatment; the association between diabetes and resistance 
was also evident among patients with a first episode of TB. TB patients with diabetes should be 
prioritized for DST in settings where it is not performed for all patients, and more (molecular) 
epidemiological and mechanistic studies are needed to unravel the factors explaining the 
association between diabetes and TB drug resistance. 
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Table. Patient characteristics and drug-resistance mutations stratified for country and diabetes  
  INDONESIA PERU 








PATIENT CHARACTERISTICS     
Male gender 52 (45%) 168 (58%) 25 (57%) 268 (60%) 
Age (years) - median (IQR) 50 (45-58) 39 (33-48) 52 (42-59) 28 (22-39) 
Previous TB treatment 24 (21%) 79 (27%) 6 (14%) 96 (22%) 
Previously diagnosed diabetes 











HIV infection 0 0 1 (2.3%) 18 (4.0%) 



























DRUG RESISTANCE MUTATIONS     
Any drug resistance 21 
(18.3%) 
44 (15.1%) 17 (38.6%) 88 (19.8%) 





































































































Drug resistance data represent the number (%) of isolates with at least one mutation in the respective 
gene.  
* P-value <0.05; ** P-value <0.01 (p-values are Chi-square p-values unless the expected number of 
resistant isolates equalled less than 5, in which case the Fisher’s Exact Test p-value was calculated). 
IQR: interquartile range; HIV: human immunodeficiency virus; NA: not applicable. 
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